ALEC

ALEC

USD

Alector Inc. Common Stock

$1.320-0.080 (-5.714%)

实时价格

Healthcare
生物技术
美国

价格图表

Loading Chart...

关键指标

市场指标
公司基本面
交易统计

市场指标

开盘价

$1.400

最高价

$1.435

最低价

$1.290

成交量

1.77M

公司基本面

市值

133.6M

所属行业

生物技术

国家/地区

United States

交易统计

平均成交量

2.62M

交易所

NMS

货币

USD

52周价格范围

最低价 $0.87当前价 $1.320最高价 $6.14

相关新闻

Analyst Upgrades

Clinical Failure Halts Alector's Dementia Program, Company Reduces Workforce

Alector's Phase 3 trial for FTD-GRN drug, latozinemab, failed the clinical co-primary endpoint. The program is discontinued; Alector cuts 49% of staff.

查看更多
Clinical Failure Halts Alector's Dementia Program, Company Reduces Workforce
Analyst Upgrades

TD Cowen Downgrades Alector to Hold

TD Cowen analyst Yaron Werber downgrades Alector from Buy to Hold.

查看更多
Analyst Upgrades

Cantor Fitzgerald Downgrades Alector to Neutral

Cantor Fitzgerald analyst Pete Stavropoulos downgrades Alector from Overweight to Neutral.

查看更多
Analyst Upgrades

HC Wainwright & Co. Maintains Buy on Alector, Lowers Price Target to $5

HC Wainwright & Co. analyst Andrew Fein maintains Alector with a Buy and lowers the price target from $10 to $5.

查看更多
HC Wainwright & Co. Maintains Buy on Alector, Lowers Price Target to $5
Analyst Upgrades

William Blair Downgrades Alector to Market Perform

William Blair analyst Myles Minter downgrades Alector from Outperform to Market Perform.

查看更多
Analyst Upgrades

BTIG Downgrades Alector to Neutral

BTIG analyst Thomas Shrader downgrades Alector from Buy to Neutral.

GlobeNewswire

Alector Announces Topline Results from Latozinemab Phase 3 Trial in Individuals with Frontotemporal Dementia Due to a GRN Mutation and Provides Business Update

SOUTH SAN FRANCISCO, Calif., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (NASDAQ:ALEC), a clinical-stage biotechnology company focused on developing therapies to counteract the devastating progression of